GD
ALNY icon

Grandfield & Dodd’s Alnylam Pharmaceuticals ALNY Stock Holding History

Grandfield & Dodd’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.02M Sell
3,081
-48
-2% -$16.3K 0.06% 108
2025
Q4 		$1.24M Buy
3,129
+9
+0.3% +$3.98K 0.07% 105
2025
Q3 		$1.42M Buy
3,120
+68
+2% +$27.7K 0.08% 100
2025
Q2 		$995K Buy
3,052
+20
+0.7% +$5.53K 0.06% 109
2025
Q1 		$819K Buy
3,032
+659
+28% +$169K 0.05% 111
2024
Q4 		$558K Buy
2,373
+1,149
+94% +$302K 0.03% 135
2024
Q3 		$337K Buy
+1,224
New +$319K 0.02% 164

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Grandfield & Dodd's ALNY Position: Q1 2026 in Review

Grandfield & Dodd reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.5% in Q1 2026, selling an estimated $16.3K and leaving 3,081 shares worth $1.02M. The position accounts for 0.06% of the portfolio, ranked #108.

Grandfield & Dodd first reported a position in ALNY in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.42M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Grandfield & Dodd held 3,081 shares of Alnylam Pharmaceuticals worth $1.02M as of Q1 2026.
  • Grandfield & Dodd sold 48 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
  • Alnylam Pharmaceuticals made up 0.06% of Grandfield & Dodd's portfolio in Q1 2026, its #108 holding.
  • Grandfield & Dodd first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • Grandfield & Dodd's Alnylam Pharmaceuticals position peaked at $1.42M in Q3 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.